Consequently, we should develop innovative strategies, such as using lipid nanoparticles for targeted delivery of siRNA (138, 139), for example, ZDHHC5 siRNA to reduce vascular inflammation in atherosclerosis models, or employing enzyme-responsive prodrug activation systems, such as releasing APT1 inhibitors at sites of high oxLDL expression. This evidence concerns the gene FAS and atherosclerosis.